Download Switzerland Report - The European Times

Canton of Zurich
Pfizer Switzerland is based in the
canton of Zurich, unlike many global
pharmaceutical enterprises which
chose Basel as their base in Switzerland.
Explaining why Pfizer picked
Zurich, Dr. Ralph Studer says, “Zurich
is one of the world’s cities with the
highest quality of life. With our
European headquarter for the “Established
Products”-part of the business
located in Zurich, we profit from a
high-level infrastructure, including
close proximity to the airport
(approximately 10 minutes) and
many competitive advantages. Zurich
is an exceptionally friendly environment
for global companies. We have
political stability here, with incredibly
favorable working conditions. There
are many positive points.”
Support for local initiatives
Pfizer Switzerland has formed a
number of local alliances, including
with the University of Zurich and its
Pfizer research foundation has made
major investments in local life sciences
initiatives. “We have invested €3.3
million (CHF4.75 million) * in award
money for research achievements to
date. We grant an annual award of
€20,920 (CHF30,000) * up to €83,682
(CHF120,000) * distributed to local
scientists who are particularly innovative
in their respective fields,” Dr.
Ralph Studer points out. Pfizer Switzerland
also supports the Swiss Heart
Foundation.
Partnering in research efforts
Pfizer, both in Switzerland and
worldwide, will continue to focus on
research and development, both on
its own and in partnership with other
companies. Dr. Ralph Studer explains,
“We build business development partnerships
with other organisations
to find innovative technologies and
common ways of working together
*
Exchange rate by April, 2010: 1e=1.434 CHF; 1e=1.340 US$
and furthering research in all areas of
life sciences.”
Dr. Ralph Studer is very positive
about Pfizer’s future. He notes that
the company, both in Switzerland
and worldwide, works closely with
local authorities and has developed
long-term strategies which continue
to focus on innovation. He says,
“We are committed to growth, and
we are prepared for the future. In
Switzerland we have one of the best
healthcare systems, due to the development
of drugs and innovation in
the pharmaceutical industry, and
also because of our significant investment
in research and development of
approximately €5.8 billion (US$7.8
billion) * worldwide. This will allow us
to continue to adapt to the industry’s
ever evolving market.”
Concerning the particular role Pfizer
Switzerland will play in the coming
years, Dr. Ralph Studer says, “Pfizer
Pfizer Building © Eduard Hueber/archphoto.com
has the commitment to put the
patient and the customer in the centre
of everything we do and to leverage
on the knowledge and the synergies
of all countries across Europe. We
try to contribute with positive signals
from Switzerland throughout the
region. We believe in working with
other leading sectors and institutions,
because we know only by doing this we
can truly prosper in the international
community.”
Pfizer AG
Schärenmoosstrasse 99
CH-8052 Zürich
Switzerland
Tel. +41 (0)43 495 71 11
Fax: +41 (0)43 495 72 80
info.ch@pfizer.com
www.pfizer.ch, www.pfizer.com
65